Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers in Clozapine-responding Schizophrenia
Sponsor: Jimmi Nielsen
Summary
The outline of the current project is to establish a cohort of patients with treatment refractory schizophrenia eligible for clozapine, to identify clinical and biological characteristics of clozapine responding patients. Patients will be offered treatment with clozapine according to national clinical guidelines. Before clozapine is initiated, patients will be offered a thoroughly neurobiological examination, and re-examination will be carried out after 12 weeks of treatment. The primary focus of the examinations will be immunological markers and autoantibodies in the blood and cerebrospinal fluid, permeability of the blood-brain barrier and magnetic resonance imaging of structural, neurochemical and functional brain changes.
Key Details
Gender
All
Age Range
18 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2021-02-28
Completion Date
2029-12-31
Last Updated
2026-01-20
Healthy Volunteers
No
Conditions
Interventions
Clozapine
clinical doses adjusted to sideeffects and clinical effect
Locations (1)
Mental Health Services Glostrup, Unit for Complicated Schizophrenia
Glostrup Municipality, Denmark, Denmark